Literature DB >> 22828007

Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control.

Ruchika Batra1, Rajen Tailor, Shabbir Mohamed.   

Abstract

PURPOSE: To describe a series of 4 patients with inadequately controlled primary open angle glaucoma and ocular surface disease (OSD) in whom a combination approach was used to manage the OSD resulting in improved intraocular pressure (IOP) control. PATIENTS AND METHODS: A retrospective review of the clinical notes of 4 patients referred to a tertiary surgical glaucoma service was performed. At the initial visit, measures to control the OSD were employed in all patients; twice-daily lid hygiene measures, a 3-month course of 50 mg daily oral doxycycline, topical carmellose sodium (celluvisc) 0.5% 4 to 6 times daily, and preservative-free equivalents of topical antiglaucoma medications as deemed appropriate, depending on the perceived severity of the OSD.
RESULTS: Patients were reviewed for a maximum of 24 months after intervention. In all patients treatment resulted in a marked symptomatic and clinical improvement in the ocular surface with a reduction in hyperemia, meibomian gland dysfunction and superficial keratopathy. A reduction in the IOP also occurred in all patients, obviating the need for glaucoma drainage surgery during the study period.
CONCLUSIONS: Patients with severe OSD often have glaucoma that is refractive to medical therapy. Furthermore, the surgical success of glaucoma filtering surgery is compromised in patients with scarring and inflammation of the conjunctiva. The term we postulate is "OSD exacerbated glaucoma." This is the first study to suggest that the use of a combination approach comprising medical treatment to manage the OSD in patients with primary open angle glaucoma may lead to an improvement in the IOP control and the management of glaucoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 22828007     DOI: 10.1097/IJG.0b013e318264cd68

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  16 in total

1.  Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells.

Authors:  Yi Zhang; Wendy R Kam; Yang Liu; Xiaomin Chen; David A Sullivan
Journal:  Cornea       Date:  2017-06       Impact factor: 2.651

2.  Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease.

Authors:  Ujwala S Saboo; Francisco Amparo; Hasanain Shikari; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-12       Impact factor: 3.117

3.  Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials.

Authors:  Jo-Hsuan Wu; Sheng-Nan Chang; Takashi Nishida; Bo-I Kuo; Jou-Wei Lin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-07       Impact factor: 3.117

4.  Prostaglandin E2 and F2α Alter Expression of Select Cholesteryl Esters and Triacylglycerols Produced by Human Meibomian Gland Epithelial Cells.

Authors:  Jillian F Ziemanski; Landon Wilson; Stephen Barnes; Kelly K Nichols
Journal:  Cornea       Date:  2022-01-01       Impact factor: 3.152

5.  Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.

Authors:  Xi Han; Yang Liu; Wendy R Kam; David A Sullivan
Journal:  Exp Eye Res       Date:  2018-02-13       Impact factor: 3.467

6.  Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension.

Authors:  Omer Ersin Muz; Kenan Dagdelen; Tuncay Pirdal; Mete Guler
Journal:  Int Ophthalmol       Date:  2021-07-14       Impact factor: 2.031

7.  European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options.

Authors: 
Journal:  Br J Ophthalmol       Date:  2017-06       Impact factor: 4.638

Review 8.  False Myths versus Medical Facts: Ten Common Misconceptions Related to Dry Eye Disease.

Authors:  Giuseppe Giannaccare; Vincenzo Scorcia
Journal:  Biomedicines       Date:  2020-06-24

Review 9.  Ocular benzalkonium chloride exposure: problems and solutions.

Authors:  Michael H Goldstein; Fabiana Q Silva; Nysha Blender; Trung Tran; Srilatha Vantipalli
Journal:  Eye (Lond)       Date:  2021-07-14       Impact factor: 4.456

Review 10.  Glaucoma therapy: preservative-free for all?

Authors:  John Thygesen
Journal:  Clin Ophthalmol       Date:  2018-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.